Infertility linked to post-childbrith onset of systemic autoimmune disease Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a… https://t.co/NJf44KJ2Hc https://t.co/W4rhsDHoqB

BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/4Bz3Vq93jH https://t.co/ZhwKZ4XmNy

• Advances in the management of psoriatic arthritis in adults

JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar - Dx often delayed 6-8 yrs - Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/UbqVOr2iDx https://t.co/Ye5mYcbYX2

Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/dWvBjXgAIh https://t.co/YWmdqJrijf

• Periarticular Cutaneous Nodules and Symmetric Polyarthralgia With an Insidious …

Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/kGPSXSYEZI https://t.co/RtwSRnzeU0

Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf

• U.S. FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 biosimilar to J&J's St…

Ozempic will change rheumatology @drdavidliew Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/4gujykjDCa https://t.co/RLG1vA57kC

Novel TYK2 inhibitor Zasocitinib Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/KbHcgSIohv https://t.co/0g8X4zrq4X

ACR24 JAK TYK Topic Panel https://t.co/SzurEICVxr https://t.co/m6cKyA4BBv

• ACR24 JAK TYK Topic Panel | RheumNow

FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1

Inebilizumab for Treatment of IgG4-Related Disease Inebilizumab is a monoclonal antibody that depletes CD19+ B cells and has been studied in adults with IgG4-related disease. In a phase 3, double-blind, randomized, placebo-controlled trial, it reduced IgG4-related disease… https://t.co/7PAmCn9O2I https://t.co/NmNA1p6GmI

Phase 2b Study of Ianalumab in Sjögren's A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD). https://t.co/08W0N1f3ap https://t.co/lyZwGI56Qq

• Phase 2b Study of Ianalumab in Sjögren's | RheumNow

ICYMI: Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/94i7NZGSJH https://t.co/XiSLNaLuf9